JP2011505810A - ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 - Google Patents

ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 Download PDF

Info

Publication number
JP2011505810A
JP2011505810A JP2010537235A JP2010537235A JP2011505810A JP 2011505810 A JP2011505810 A JP 2011505810A JP 2010537235 A JP2010537235 A JP 2010537235A JP 2010537235 A JP2010537235 A JP 2010537235A JP 2011505810 A JP2011505810 A JP 2011505810A
Authority
JP
Japan
Prior art keywords
antibody
human
cells
variable region
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010537235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505810A5 (enExample
Inventor
クオ，ヤジュン
チエン，ウェイツゥ
ホウ，シェン
リ，ボフア
ワン，ハオ
マ，ジン
Original Assignee
シャンハイ グオジアン バイオ−テック インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200710094456 external-priority patent/CN101245108B/zh
Application filed by シャンハイ グオジアン バイオ−テック インスティチュート filed Critical シャンハイ グオジアン バイオ−テック インスティチュート
Publication of JP2011505810A publication Critical patent/JP2011505810A/ja
Publication of JP2011505810A5 publication Critical patent/JP2011505810A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010537235A 2007-12-13 2008-12-03 ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 Ceased JP2011505810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 200710094456 CN101245108B (zh) 2007-12-13 2007-12-13 抗人cd34抗体、其制备方法及用途
CN200810043016 2008-01-08
PCT/CN2008/001963 WO2009079922A1 (en) 2007-12-13 2008-12-03 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof

Publications (2)

Publication Number Publication Date
JP2011505810A true JP2011505810A (ja) 2011-03-03
JP2011505810A5 JP2011505810A5 (enExample) 2012-01-26

Family

ID=40800709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537235A Ceased JP2011505810A (ja) 2007-12-13 2008-12-03 ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用

Country Status (6)

Country Link
US (1) US20100311955A1 (enExample)
EP (1) EP2233501B1 (enExample)
JP (1) JP2011505810A (enExample)
BR (1) BRPI0821211A2 (enExample)
CA (1) CA2708407A1 (enExample)
WO (1) WO2009079922A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4086338A1 (en) * 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
TWI443107B (zh) 2011-12-29 2014-07-01 Ind Tech Res Inst 人源化之抗人類細胞表面抗原ｃｄ３４之單株抗體及其應用
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US10604586B2 (en) * 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN109265547B (zh) * 2018-07-23 2022-07-26 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4466019A4 (en) * 2022-01-21 2026-01-07 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES COMPRISING A G6B BINDER AND/OR A CD34 BINDER AND THEIR USES
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118501458B (zh) * 2024-05-08 2025-09-30 广东省第二人民医院（广东省卫生应急医院） 一种外周血细胞外囊泡表面多种免疫标志物联合检测的试剂盒及方法
WO2026156792A1 (zh) * 2025-01-26 2026-07-30 深圳华大生命科学研究院 Cd34抗体及其应用
CN120098129B (zh) * 2025-03-03 2026-04-03 安徽医科大学第一附属医院 一种具有信号蛋白标签的cd34生物融合酶抗体及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11332594A (ja) * 1998-05-26 1999-12-07 Asahi Chem Ind Co Ltd Ｃｄ４陽性細胞の分離装置および分離方法
JPH11332578A (ja) * 1998-05-25 1999-12-07 Asahi Chem Ind Co Ltd 細胞の分離装置及び分離方法
US20070207210A1 (en) * 2004-05-12 2007-09-06 Brown Larry R Protein Microspheres Retaining Pharmacokinetic and Pharmacodynamic Properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU3733499A (en) * 1998-05-25 1999-12-13 Asahi Kasei Kogyo Kabushiki Kaisha Cell separation device and separation method
ATE382633T1 (de) * 2000-05-23 2008-01-15 Baxter Healthcare Sa Reagenzien zur zellselektion und verfahren zur anwendung
CN101245108B (zh) * 2007-12-13 2013-04-10 上海抗体药物国家工程研究中心有限公司 抗人cd34抗体、其制备方法及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11332578A (ja) * 1998-05-25 1999-12-07 Asahi Chem Ind Co Ltd 細胞の分離装置及び分離方法
JPH11332594A (ja) * 1998-05-26 1999-12-07 Asahi Chem Ind Co Ltd Ｃｄ４陽性細胞の分離装置および分離方法
US20070207210A1 (en) * 2004-05-12 2007-09-06 Brown Larry R Protein Microspheres Retaining Pharmacokinetic and Pharmacodynamic Properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013045111; ＯＴＴＯ，Ｍ．　ｅｔ　ａｌ．: 'Ｓｅｌｅｃｔｉｏｎ　ｏｆ　ｓｔｅｍ　ｃｅｌｌｓ　ｂｙ　ｕｓｉｎｇ　ａｎｔｉｂｏｄｉｅｓ　ｔｈａｔ　ｔａｒｇｅｔ　ｄｉｆｆｅｒｅｎｔ　ＣＤ３４　ｅｐｉｔｏｐｅｓ　ｙｉｅｌｄｓ　ｄｉｆｆｅｒｅｎｔ　ｐａｔ' Ｓｔｅｍ　Ｃｅｌｌｓ Ｖｏｌ．２５，　Ｎｏ．２, 200702, ｐｐ．５３７-４２ *
JPN6013045112; ＨＯＵ，Ｓ．　ｅｔ　ａｌ．: 'Ｈｕｍａｎｉｚａｔｉｏｎ　ｏｆ　ａｎ　ａｎｔｉ-ＣＤ３４　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　ｂｙ　ｃｏｍｐｌｅｍｅｎｔａｒｉｔｙ-ｄｅｔｅｒｍｉｎｉｎｇ　ｒｅｇｉｏｎ　ｇｒａｆｔｉｎｇ　ｂａｓｅ' Ｊ．　Ｂｉｏｃｈｅｍ． Ｖｏｌ．１４４，　Ｎｏ．１, 200807, ｐｐ．１１５-２０ *
JPN6013045114; ＱＩＡＮ，Ｗ．　ｅｔ　ａｌ．: 'Ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ｎｅｗ　ｖｅｒｓｉｏｎｓ　ｏｆ　ａｎｔｉ-ｈｕｍａｎ　ＣＤ３４　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｉｅｓ　ｗｉｔｈ　ｐｏｔｅｎｔｉａｌｌｙ　ｒｅｄｕｃｅｄ　ｉｍｍｕｎｏ' Ｂｉｏｃｈｅｍ．　Ｂｉｏｐｈｙｓ．　Ｒｅｓ．　Ｃｏｍｍｕｎ． Ｖｏｌ．３６７，　Ｎｏ．２, 20080307, ｐｐ．４９７-５０２ *

Also Published As

Publication number Publication date
US20100311955A1 (en) 2010-12-09
EP2233501A1 (en) 2010-09-29
EP2233501B1 (en) 2012-07-11
WO2009079922A1 (en) 2009-07-02
EP2233501A4 (en) 2010-12-01
BRPI0821211A2 (pt) 2015-06-16
CA2708407A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
EP2233501B1 (en) Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
SA112330278B1 (ar) مواد ضابطة جديدة وطرق للاستخدام
CN110526971A (zh) 抗-CD38抗体和与致弱干扰素α-2B的融合体
CN108164600B (zh) 一种抗gpc3抗体及其制备方法和用途
KR102960935B1 (ko) 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
CN112646032A (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
EP4458853A1 (en) Development of novel upar single-domain antibody
CN113383017A (zh) 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体
WO2023125888A1 (zh) 一种gprc5d抗体及其应用
WO2022247804A1 (zh) 抗gprc5d抗体、其制备方法与用途
CN116848147A (zh) Cd19人源化抗体及其应用
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
CN116685350A (zh) 抗cd22的纳米抗体及其用途
CN101245108B (zh) 抗人cd34抗体、其制备方法及用途
CN120965881A (zh) 抗猪b细胞表面cd27的抗体或其抗原结合片段及其组合物和应用
CN120795156A (zh) 抗猪b细胞表面cd19的抗体或其抗原结合片段及其组合物和应用
CN117209608A (zh) 一种靶向cd47的抗体及其应用
CN110615841B (zh) 抗人cd47单克隆抗体及其应用
CN118420758A (zh) 人源化的结合cd19的抗体或cd19抗原结合片段及应用
CN101481417A (zh) 抗人cd34人源化抗体、其制备方法及用途
CN114478770A (zh) 抗体及其制备方法
CN114075285A (zh) 抗人cd38人源化单克隆抗体及其应用
CN120965882B (zh) 抗猪b细胞表面cd20的抗体或其抗原结合片段及其组合物和应用
CN115724979B (zh) 一种多功能重组抗体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140128